FCM
CMPX icon

Farallon Capital Management’s Compass Therapeutics CMPX Stock Holding History

Farallon Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-582,750
Closed -$798K – 317
2022
Q1 		$798K Sell
582,750
-417,250
-42% -$862K ﹤0.01% 227
2021
Q4 		$3.17M Buy
+1,000,000
New +$3.32M 0.02% 200

Other funds holding CMPX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

Farallon Capital Management's CMPX Position: Q2 2022 in Review

Farallon Capital Management sold out of Compass Therapeutics (CMPX) in Q2 2022, closing a stake of 582,750 shares — an estimated $798K sold.

Farallon Capital Management first reported a position in CMPX in Q4 2021 and held it in 2 quarters. The position peaked at $3.17M in Q4 2021. 34 funds tracked by Wall St. Rank hold CMPX as of Q2 2022.

  • Farallon Capital Management reported no remaining Compass Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Farallon Capital Management sold 582,750 Compass Therapeutics shares in Q2 2022, an estimated $798K.
  • Farallon Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 2 quarters.
  • Farallon Capital Management's Compass Therapeutics position peaked at $3.17M in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2022.

Based on Farallon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.